Literature DB >> 11251164

Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.

S Miyamoto1, A Ochiai, N Boku, A Ohtsu, M Tahara, S Yoshida, H Okabe, T Takechi, M Fukushima.   

Abstract

The relationships between gene expression, protein expression, and enzymatic activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) have not been clarified in tumor and non-tumor tissues of human. In this study, we compared three different parameters by evaluating TS and DPD levels, mRNA expression assessed by RT-PCR, protein expression evaluated by immunohistochemical examination, and enzymatic activity measured by biochemical assay, in the tumor tissue and adjacent normal mucosa of 43 patients with gastrointestinal cancer. TS enzymatic activity in the tumor tissue was significantly higher than in normal tissue in both the stomach (median activity: 81.0 and 38.0 pmol/mg protein, respectively, p=0.012) and the colorectum (49.8 and 30.8, respectively, p=0.023). Similarly, TS mRNA expression in the tumor tissue was significantly higher than in normal tissue in both the stomach (median TS/GAPDH ratio: 6.0 and 2.0, respectively, p=0.009) and the colorectum (3.20 and 0.91, respectively, p=0.001). But no significant differences in DPD activity were observed between the tumor and normal tissue in either stomach (median activity: 41.3 and 41.6 pmol/min/mg protein, respectively) or colorectum (34.9 and 49.0, respectively). On the other hand, DPD mRNA levels in normal tissue were significantly higher than in tumor tissue only in the colorectum (DPD/GAPDH ratio: 0.83 and 0.20, respectively, p=0.003). No linear relationships were found between the enzymatic activity and mRNA expression of TS or DPD either in tumor or normal tissue. Nor were any correlations found between protein expression and either mRNA expression or enzymatic activity for either TS or DPD. These results suggest that tissue TS and DPD levels may vary with differences in the methods used to measure them. These discrepancies must be taken into account when interpreting correlation between TS and DPD levels and clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251164     DOI: 10.3892/ijo.18.4.705

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.

Authors:  Steven M Offer; Gabriel L Butterfield; Calvin R Jerde; Croix C Fossum; Natalie J Wegner; Robert B Diasio
Journal:  Mol Cancer Ther       Date:  2014-01-08       Impact factor: 6.261

2.  Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.

Authors:  Jin Ho Baek; Jong Gwang Kim; Shi Nae Kim; Dong Hwan Kim; Sang Kyun Sohn; Young Jun Hong; Kyu Bo Lee
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

3.  Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Authors:  Silke Lassmann; Michael Hennig; Robert Rosenberg; Jörg Nährig; Joachim Schreglmann; Friedemann Krause; Manuela Poignee-Heger; Hjalmar Nekarda; Heinz Höfler; Martin Werner
Journal:  Int J Colorectal Dis       Date:  2005-08-13       Impact factor: 2.571

4.  Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study.

Authors:  Takenori Takahata; Jugoh Itoh; Taroh Satoh; Atsushi Ishiguro; Yoshifumi Matsumoto; Satoshi Tanaka; Soh Saitoh; Hiroshi Tohno; Shinsaku Fukuda; Yasuo Saijo; Yuh Sakata
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

5.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

Review 6.  Molecular predictors of treatment and outcome in colorectal cancer.

Authors:  Syma Iqbal; Heinz-Josef Lenz
Journal:  Curr Gastroenterol Rep       Date:  2003-10

Review 7.  Reprogramming of Fatty Acid Metabolism in Gynaecological Cancers: Is There a Role for Oestradiol?

Authors:  Azilleo Kristo Mozihim; Ivy Chung; Nur Akmarina B M Said; Amira Hajirah Abd Jamil
Journal:  Metabolites       Date:  2022-04-14

8.  (-)-Epicatechin Prevents Blood Pressure Increase and Reduces Locomotor Hyperactivity in Young Spontaneously Hypertensive Rats.

Authors:  M Kluknavsky; P Balis; A Puzserova; J Radosinska; A Berenyiova; M Drobna; S Lukac; J Muchova; I Bernatova
Journal:  Oxid Med Cell Longev       Date:  2016-11-03       Impact factor: 6.543

9.  Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.

Authors:  Wei Yu; Ryan A Denu; Kimberly A Krautkramer; Kreg M Grindle; David T Yang; Fotis Asimakopoulos; Peiman Hematti; John M Denu
Journal:  J Biol Chem       Date:  2015-12-02       Impact factor: 5.486

10.  The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.

Authors:  Jamie M Aye; Laura L Stafman; Adele P Williams; Evan F Garner; Jerry E Stewart; Joshua C Anderson; Smitha Mruthyunjayappa; Mary G Waldrop; Caroline D Goolsby; Hooper R Markert; Colin Quinn; Raoud Marayati; Elizabeth Mroczek-Musulman; Christopher D Willey; Karina J Yoon; Kimberly F Whelan; Elizabeth A Beierle
Journal:  Oncotarget       Date:  2019-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.